Introduction
============

In the 2008 publication of WHO (World Health Organization) classification of hematological malignancies, infectious agents including HCV (Hepatitis C Virus) have been implicated in several types of non-Hodgkin's lymphoma (NHL).[@b1-mjhid-11-1-e2019011] WHO estimates that about 3% of the world's population has been infected with HCV and that there are more than 170 million chronic carriers.[@b2-mjhid-11-1-e2019011] HCV is an RNA hepatotropic and lymphotrophic virus, replicating within the B cells and triggering lymphomagenesis.[@b3-mjhid-11-1-e2019011] Despite etiologic heterogeneity among NHL subtypes,[@b4-mjhid-11-1-e2019011] several studies have shown a higher prevalence rate of HCV in B-NHL cases in comparison to controls.[@b5-mjhid-11-1-e2019011],[@b6-mjhid-11-1-e2019011] Globally, approximately 8% of NHL may be attributable to HCV.[@b8-mjhid-11-1-e2019011] The EPILYMPH consortium documented an almost two-fold increased risk of NHL in patients with chronic HCV infection compared to HCV negative control.[@b9-mjhid-11-1-e2019011],[@b10-mjhid-11-1-e2019011] This increased risk may be more dramatically evident in populations with high HCV prevalence.[@b10-mjhid-11-1-e2019011],[@b7-mjhid-11-1-e2019011] Egypt has a very high prevalence of HCV: according to Egypt Demographic and Health Survey 2008 (EDHS, 2008), HCV prevalence reaches 14.7 % in 15--59 years age group.[@b11-mjhid-11-1-e2019011] This percentage is even higher in rural areas.[@b12-mjhid-11-1-e2019011] Approximately 8--10 million Egyptians have serological evidence of HCV infection.[@b13-mjhid-11-1-e2019011],[@b14-mjhid-11-1-e2019011] Interestingly, the WHO Glocobocan Project for cancer incidence and mortality, reported that NHL, is the 5^th^ malignancy in Egypt in both genders compared to the 12^th^ place in Northern countries.[@b11-mjhid-11-1-e2019011] Therefore, Egypt provides a rationale for investigating the association between HCV and NHL. We performed a study in Mansoura region (Egypt) aimed to estimate the prevalence of HCV infection among B-cell NHL patients and to determine the clinical characteristics of HCV associated B-cell NHL patients in comparison to their non HCV counterpart.

Patients and Methods
====================

Study participants
------------------

Between March 2012 and March 2013, 110 patients were diagnosed with B-NHL in Mansoura Oncology Center -- Delta region, Egypt. Patients with a new NHL diagnosis were included prospectively in the present study. The inclusion and exclusion criteria were similar as for ANRS HC-13 Lympho-C study,[@b15-mjhid-11-1-e2019011] which is a large French series of patients with HCV-associated B-NHL.[@b15-mjhid-11-1-e2019011] Lymphoma staging was determined using the Ann Arbor system. Staging evaluation included physical examination, routine laboratory tests, bone marrow aspirate and biopsy when clinically relevant, computed tomography (CT). Eastern Cooperative Oncology Group performance status (ECOG PS) was recorded at lymphoma diagnosis and during each visit. The International Prognostic Index (IPI) score was calculated for DLBCL patients.[@b16-mjhid-11-1-e2019011] Their serum samples were evaluated for HCV, HBV and HIV serologies at lymphoma diagnosis. HCV positive cases were evaluated for HCV viral load. Each patient was planned to be monitored every six months for three years. Investigations were performed after approval received by Mansoura Medical Research Ethics Committee. Written informed consent to participate in the study was obtained from each subject. The study was conducted consistent with Good Clinical Practices (GCP) under the ICH guidelines and applicable national/local regulations.

Laboratory methods
------------------

Enzyme-linked immunosorbent assays (ELISA): ELISA assays were used to determine anti-HCV antibodies, Hepatitis B virus (HBV) antibodies and HBsAg and HIV antibodies (BIOTEC, UK) from serum samples of all patients. RNA isolation and quantitative real-time polymerase chain reaction: RNA was extracted from serum samples according to the manufacturer's instructions then RNA was reverse-transcribed and amplified by One Step RT-PCR QIAGEN Kit on a GeneAmp PCR system 9700. Real-time PCR was performed on the StepOne (Life Technologies). Routine laboratory testing: Transaminases (ALT & AST) serum levels were determined and expressed as IU/L, and Rheumatoid factor (RF) were determined for HCV-positive samples by turbid metric methods with cut off value \> 25 international unit/ml.

Immunohistochemical testing
---------------------------

For all patients, cyto-histological data regarding B-NHL diagnosis were recorded and categorized according to the WHO 2008 classification. Pathological materials of 22 cases of HCV+ lymphoma samples were reviewed by hematopathologist (DC) who coordinated the review of the ANRS-HC13 Lympho C study. Immunohistochemistry was performed in tumor samples following a three-step immunoperoxidase method. The antibody panel included CD20, CD3, CD5, CD10, Bcl6, Bcl2, MUM1 and Ki67.

Statistical analysis
--------------------

All statistical computations were performed using SPSS Software version 20 (IBM Corp., Armonk, New York, 2011). Continuous data were represented as the mean ± standard deviation or the median (minimum--maximum), while categorical variables were represented by frequency. Student's t-test, or Mann--Whitney test were used for comparison of continuous variables between groups while categorical data were compared between groups by using chi-square test with Yates correction. A p value of \< 0.05 was considered statistically significant. Follow-up was defined from the start of B-NHL diagnosis to the last follow-up visit. Overall survival (OS) was measured from the lymphoma diagnosis to the last follow-up or the death from any cause. The probability of OS was defined with Kaplan-Meier's method, and differences were compared with the log-rank test.

Results
=======

The study included 110 patients with NHL ([Table 1](#t1-mjhid-11-1-e2019011){ref-type="table"}). HCV infection was detected in 61% (67/110 patients) of cases. Gender-ratio did not differ between HCV positive and HCV negative patients. HCV positive patients were slightly younger than HCV negative patients (53 versus 58 years, p=0.04). Among 40 HCV positive cases with available HCV viral load, 80 % (32/40) were positive. Rheumatoid factor was positive in 23 patients out of 32 HCV RNA positive patients tested (72%). The main histological subtypes among HCV positive patients were DLBCLs (48/67 (72%)), SLL/CLL (9/67 (13%)), marginal zone lymphoma (5/67 (7.5%)) and follicular lymphoma (5/67 (7.5%)) ([Table 2](#t2-mjhid-11-1-e2019011){ref-type="table"}). Of note, none of the DLBCL reviewed samples had features of transformation from low-grade lymphoma.

Ann Arbor stage was III--IV in 78% in HCV positive studied patients. ECOG status was 0--1 in 57% of HCV positive patients. ALT and AST serum levels were higher in HCV positive NHL patients in comparison to HCV negative patients (66%versus 49%). LDH was found to be elevated in 82% of HCV positive NHL. Overall, IPI score was high/high intermediate in 78% of HCV positive patients. [Table 3](#t3-mjhid-11-1-e2019011){ref-type="table"} presents a comparison between HCV positive and HCV negative DLBCL patients. In this subgroup also, HCV-positive patients were younger and had more frequently elevated transaminases than HCV-negative patients.

All patients except eight with DLBCL and four with marginal zone lymphoma were treated with front-line treatment for lymphoma. Lymphoma management was classified according to anthracycline use into "Anthracycline containing regimen" 45 patients (67%), "Non-anthracycline containing regimen" 14 patients (24%). Forty-five patients received CHOP, 13 patients received Alkylators ± corticosteroids. Four patients received rituximab in each case associated with CHOP. One MZL patient was treated with interferon alone. With the exception of interferon, no antiviral treatment was given to these patients.

To our knowledge, 24 patients died out of the 67 HCV positive patients (36%). The median OS within the HCV positive group was 13 months (mean 21 ± 2 months) while it was 26 months (mean 25 ± 2.4 months) within the HCV negative patients (p=0.22) ([Figure 1](#f1-mjhid-11-1-e2019011){ref-type="fig"}). The median OS of the HCV positive DLBCL patients was 12.7 months (mean 18.7 ± 15.8 months) and 23.7 months ( mean 23.4 ± 15.7 months) within the HCV negative patients (p=0.37) ([Figure 2](#f2-mjhid-11-1-e2019011){ref-type="fig"}).

Discussion
==========

Confirming the role of HCV in lymphoma development, we report a strikingly high rate of HCV infection (61%) among patients with NHL in the Mansoura region, which appears to be the highest reported to our knowledge in the literature. Previous studies on the malignant complications of chronic HCV infection in Egypt or focusing specifically on the association between HCV and NHL reported an HCV prevalence ranging from 40 to 50% among patients with NHL.[@b19-mjhid-11-1-e2019011],[@b20-mjhid-11-1-e2019011],[@b21-mjhid-11-1-e2019011],[@b23-mjhid-11-1-e2019011] The higher rate we report in the Delta region may be explained by the higher prevalence of HCV in this region.

In the present study, most of the patients had DLBCL (72%). MZL was rare (7.5%). The distribution of NHL we report here is similar to previous findings in Egypt[@b19-mjhid-11-1-e2019011],[@b20-mjhid-11-1-e2019011],[@b21-mjhid-11-1-e2019011] with DLBCL proportions of 55% to 76% among HCV associated NHL, MZL proportion being lower than 10%.[@b21-mjhid-11-1-e2019011] Overall, our results are in agreement with many studies that reported HCV association with DLBCL, and MZL.[@b6-mjhid-11-1-e2019011],[@b10-mjhid-11-1-e2019011],[@b24-mjhid-11-1-e2019011],[@b25-mjhid-11-1-e2019011] However, in Western/Northern countries most cases of HCV associated NHLs are MZL and DLBCL, being frequently transformed from low-grade lymphomas.[@b22-mjhid-11-1-e2019011] In our series, however, we did not identify such cases out of 22 cases reviewed by an expert hematopathologist (DC). The different distribution might be due to the unique environmental background or to differences in access to care. We cannot exclude that patients with low-grade lymphomas are underdiagnosed in Southern countries.

It would be interesting to confirm this finding in a larger number of pathological samples from patients with HCV-associated lymphomas in Southern countries. The low frequency of low-grade lymphoma in the study is consistent with other studies in Egypt although it strongly contrasts with the distribution of HCV associated lymphomas in Northern countries.

We did not find unique clinical or biological characteristics associated with HCV infection in lymphoma patients. This was previously reported in an Egyptian study performed on 132 DLBCL patients among whom 26.5% had HCV. There was indistinguishable demography for this group compared to HCV-negative patients.[@b21-mjhid-11-1-e2019011] Additionally, another Egyptian study comparing HCV infected and HCV uninfected patients with NHL showed no statistically significant difference in age, sex, clinical presentation, stage, IPI score, LDH level, pathological type, and chemotherapy regimen.[@b24-mjhid-11-1-e2019011] Of note in our population, HCV infected patients were younger and had more frequent elevated transaminases. Rheumatoid factor activity was positive in two-thirds of our population of HCV associated NHL, supporting a role of chronic antigenic stimulation on lymphomagenesis. These observations are similar to those reported in the Lympho C Study.[@b15-mjhid-11-1-e2019011] Overall, there was a trend for a pejorative impact of HCV infection on OS.

In our study, only one patient had access to antiviral therapy for their HCV infection. Recently, a subcommittee of the Egyptian National Commission for Viral Hepatitis was assigned to prioritize access to direct antivirals in patients with extrahepatic manifestations. HCV patients with Non-Hodgkin B-cell lymphoma were attributed the highest score according to relative urgency, and expected benefit of treatment.[@b26-mjhid-11-1-e2019011] Antiviral approaches should be evaluated in Egypt to improve the outcome of HCV associated NHL patients since many studies in Northern/Western countries demonstrated high rates of response after a successful front-line antiviral treatment (IFN and now Direct Antiviral Agents).[@b27-mjhid-11-1-e2019011],[@b28-mjhid-11-1-e2019011],[@b29-mjhid-11-1-e2019011]

Conclusions
===========

Our study results confirmed the association between HCV infection and risk of NHL. Prevention and treatment of HCV infection may decrease NHL incidence, especially in areas with a high prevalence of HCV. Patients with NHL and their physicians should be aware of the high prevalence of chronic HCV infection in NHL in Egypt and patients should be routinely screened for HCV infection especially in endemic areas like delta region, Egypt. The access to antiviral drugs should be extended in these regions, and their impact on the clinical course of NHL should be evaluated in Egypt.
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###### 

Characteristics of HCV positive and HCV negative patients with B-cell Non-Hodgkin Lymphoma (n=110).

                                                                  HCV          HCV           p-value
  --------------------------------------------------------------- ------------ ------------- ---------
  **Gender ratio (M/F)**                                          37/30(1.2)   26/17(1.5)    0.69
  **Age (years), mean \[±SD\]**                                   53\[± 13\]   58 \[± 11\]   0.04
  **Ann Arbor Stage**                                                                        0.27
  **1--2**                                                        15(22%)      6(14%)        
  **3--4**                                                        52(78%)      37(86%)       
  **ECOG Scale**                                                                             0.006
  **0--1**                                                        38(57%)      13(30%)       
  **2--4**                                                        29(43%)      30(70%)       
  **AAIPI**[\*](#tfn1-mjhid-11-1-e2019011){ref-type="table-fn"}                              0.006
  **Low, Low-Intermediate**                                       15(22%)      4(9%)         
  **High, High-intermediate**                                     52(78%)      39(91%)       
  **Transaminases (ALT&AST)**                                                                0.08
  **Elevated**                                                    44(66%)      21(49%)       
  **Normal**                                                      23(34%)      22(51%)       
  **LDH**                                                                                    0.56
  **Elevated**                                                    35(52%)      25(58%)       
  **Normal**                                                      32(48%)      18(42%)       

AAIPI : Age Adjusted International Prognostic Index.

###### 

Comparison of B-NHL histological subtype distributions in HCV positive and HCV negative patients (N=110).

  B-NHL histological types                    HCV       HCV
  ------------------------------------------- --------- ----------
  **SLL/CLL**                                 9 (13%)   8 (19%)
  **Mantle cell lymphoma(MCL)**               0         1 (2%)
  **Follicular lymphoma (FL)**                5(7.5%)   3 (7%)
  **Marginal zone lymphoma (MZL)**            5(7.5%)   0
  **Diffuse large B cell lymphoma (DLBCL)**   48(72%)   31 (72%)

DLBCL indicates diffuse large B-cell lymphoma; FL: follicular lymphoma, MZL: marginal zone lymphoma; SLL: small lymphocytic lymphoma, MCL: Mantle cell lymphoma.

###### 

Characteristics of HCV positive and HCV negative patients with DLBCL (n=79).

                                 DLBCL Patients                
  ------------------------------ ---------------- ------------ ------------
  **Age (years)**                                              ***0.02***
  ** (Means ± SD)**              58.6± 10.9       50.8± 13.5   
  **Sex**                                                      0.89
  ** Males**                     28 (58%)         18 (58%)     
  ** Females**                   20 (42%)         13 (42%)     
  **Ann Arbor Stage**                                          0.55
  ** 1--2**                      9 (19%)          4(13%)       
  ** 3--4**                      39(81%)          27(87%)      
  **ECOG Scale**                                               0.067
  ** 0--1**                      26(54%)          10(32%)      
  ** 2--4**                      22(46%)          21(68%)      
  **AAIPI**\*                                                  ***0.02***
  ** Low, Low-Intermediate**     27(56%)          9(29%)       
  ** High, High-intermediate**   21(44%)          22(71%)      
  **Splenic involvement**                                      0.52
  ** Yes**                       8 (17%)          3 (10%)      
  ** No**                        40(83%)          28(90%)      
  **Extra-nodal sites**                                        0.49
  ** Yes**                       24(50%)          18(58%)      
  ** No**                        24(50%)          13(42%)      
  **Bone marrow involvement**                                  0.06
  ** Yes**                       13(27%)          6(19%)       
  ** No**                        28 (58%)         21(68%)      
  ** Not available**             7(15%)           4(13%)       
  **Transaminases (ALT&AST)**                                  ***0.01***
  ** Elevated**                  24(50%)          6 (19%)      
  ** Normal**                    24(50%)          25(81%)      
  **LDH**                                                      0.63
  ** Elevated**                  29 (60%)         21 (68%)     
  ** Normal**                    19(40%)          10(32%)      
                                 12.7             23.7         0.26
  **Median survival (months)**                                 
                                                               
